Oral lixivaptan effectively increases serum sodium concentrations in outpatients with euvolemic hyponatremia.
暂无分享,去创建一个
W. Abraham | D. Bichet | C. Orlandi | R. Josiassen | M. Mannelli | G. Decaux | N. Kopyt | H. Thacker | Y. Yagil
[1] W. Abraham,et al. Lixivaptan safely and effectively corrects serum sodium concentrations in hospitalized patients with euvolemic hyponatremia. , 2012, Kidney international.
[2] Warren Ho,et al. Management of hyponatremia: Providing treatment and avoiding harm , 2010, Cleveland Clinic Journal of Medicine.
[3] C. Thompson,et al. The syndrome of inappropriate antidiuretic hormone: prevalence, causes and consequences. , 2010, European journal of endocrinology.
[4] R. Schrier. Does 'asymptomatic hyponatremia' exist? , 2010, Nature Reviews Nephrology.
[5] S. Waikar,et al. Mortality after hospitalization with mild, moderate, and severe hyponatremia. , 2009, The American journal of medicine.
[6] D. Zygun,et al. The epidemiology of intensive care unit-acquired hyponatraemia and hypernatraemia in medical-surgical intensive care units , 2008, Critical care.
[7] M. Konstam,et al. Arginine Vasopressin Antagonists for the Treatment of Heart Failure and Hyponatremia , 2008, Circulation.
[8] C. Mélot,et al. Mild hyponatremia and risk of fracture in the ambulatory elderly. , 2008, QJM : monthly journal of the Association of Physicians.
[9] J. Verbalis,et al. Hyponatremia treatment guidelines 2007: expert panel recommendations. , 2007, The American journal of medicine.
[10] J. Verbalis,et al. Assessment of the Efficacy and Safety of Intravenous Conivaptan in Euvolemic and Hypervolemic Hyponatremia , 2007, American Journal of Nephrology.
[11] T. Berl,et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. , 2006, The New England journal of medicine.
[12] N. Madias,et al. Incidence and prevalence of hyponatremia. , 2006, The American journal of medicine.
[13] J. Ghali,et al. Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia. , 2006, The Journal of clinical endocrinology and metabolism.
[14] W. Abraham,et al. Aquaretic effect of lixivaptan, an oral, non-peptide, selective V2 receptor vasopressin antagonist, in New York Heart Association functional class II and III chronic heart failure patients. , 2006, Journal of the American College of Cardiology.
[15] R. Zietse,et al. Development of severe hyponatraemia in hospitalized patients: treatment-related risk factors and inadequate management. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[16] M. Manto,et al. Mild chronic hyponatremia is associated with falls, unsteadiness, and attention deficits. , 2006, The American journal of medicine.
[17] J. Verbalis,et al. Novel Vasopressin V1A and V2 Antagonist (Conivaptan) Increases Serum Sodium Concentration and Effective Water Clearance in Patients with Hyponatremia , 2004 .
[18] R. Hawkins. Age and gender as risk factors for hyponatremia and hypernatremia. , 2003, Clinica chimica acta; international journal of clinical chemistry.
[19] P. Thuluvath,et al. A vasopressin receptor antagonist (VPA‐985) improves serum sodium concentration in patients with hyponatremia: A multicenter, randomized, placebo‐controlled trial , 2003, Hepatology.
[20] A. Patat,et al. Pharmacodynamic effects of a nonpeptide antidiuretic hormone V2 antagonist in cirrhotic patients with ascites , 2002, Hepatology.
[21] J. Taylor,et al. VPA-985, a nonpeptide orally active and selective vasopressin V2 receptor antagonist. , 1998, Advances in experimental medicine and biology.
[22] L. Rubenstein,et al. Hyponatremia in a Nursing Home Population , 1995, Journal of the American Geriatrics Society.
[23] R. Anderson,et al. Hospital-associated hyponatremia. , 1986, Kidney international.
[24] M. Kleinfeld,et al. Hyponatremia As Observed in a Chronic Disease Facility , 1979, Journal of the American Geriatrics Society.